An AI model can accurately flag EGFR mutations in lung adenocarcinoma using routine pathology slides, reducing the need for rapid genetic tests.
Key Details
- 1Researchers from Mount Sinai, Memorial Sloan Kettering, and collaborators published results in Nature Medicine on July 9, 2025.
- 2The AI model predicts EGFR mutations from H&E-stained pathology slides of lung adenocarcinoma.
- 3A live 'silent trial' at Memorial Sloan Kettering showed the model could reduce rapid genetic testing by over 40%.
- 4The model was trained and validated on the largest multi-institutional dataset of matched slides and sequencing results from the US and Europe.
- 5Preserving tissue by avoiding unnecessary rapid tests allows for more comprehensive genomic sequencing.
- 6Work is ongoing to broaden the model's biomarker detection and deploy it in more healthcare settings.
Why It Matters
This study demonstrates the practical integration of AI in pathology workflows, expediting precision therapy decisions and optimizing tissue usage in lung cancer diagnostics. It signals a major step toward AI-driven personalization in oncology, with potential to improve both efficiency and patient outcomes.
Source
EurekAlert
Related News
•EurekAlert
Study Warns: AI Alone Is Not Enough in Critical Healthcare Decisions
Evaluating both AI algorithms and human users is key for safe adoption in high-stakes healthcare settings, according to an Ohio State study.
•EurekAlert
AI Dramatically Improves Prediction of Delivery Timing from Ultrasound Images
Ultrasound AI's study validates advanced AI for predicting delivery timing using standard ultrasound images.
•EurekAlert
AI Voice Analysis Shows Promise for Early Laryngeal Cancer Detection
Researchers demonstrated AI could detect early laryngeal cancer from voice recordings, distinguishing it from benign conditions.